|
ES2553449T3
(es)
|
2011-07-06 |
2015-12-09 |
Gilead Sciences, Inc. |
Compuestos para el tratamiento de VIH
|
|
US10280169B2
(en)
|
2013-12-11 |
2019-05-07 |
Biogen Ma Inc. |
Biaryl bruton's tyrosine kinase inhibitors
|
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
|
TW201613936A
(en)
|
2014-06-20 |
2016-04-16 |
Gilead Sciences Inc |
Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
|
|
NO2717902T3
(enExample)
|
2014-06-20 |
2018-06-23 |
|
|
|
US20160067255A1
(en)
|
2014-09-04 |
2016-03-10 |
Gilead Sciences, Inc. |
Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
|
|
TWI738321B
(zh)
|
2014-12-23 |
2021-09-01 |
美商基利科學股份有限公司 |
多環胺甲醯基吡啶酮化合物及其醫藥用途
|
|
TW202237569A
(zh)
|
2014-12-24 |
2022-10-01 |
美商基利科學股份有限公司 |
喹唑啉化合物
|
|
ES2735087T3
(es)
|
2014-12-24 |
2019-12-16 |
Gilead Sciences Inc |
Compuestos de pirimidina fusionados para el tratamiento de VIH
|
|
EP3237397B1
(en)
|
2014-12-24 |
2018-11-21 |
Gilead Sciences, Inc. |
Isoquinoline compounds for the treatment of hiv
|
|
DK3097102T3
(en)
|
2015-03-04 |
2018-01-22 |
Gilead Sciences Inc |
TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO [3,2-D] PYRIMIDINE COMPOUNDS
|
|
TR201905009T4
(tr)
|
2015-04-02 |
2019-05-21 |
Gilead Sciences Inc |
Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
|
|
JP2018525412A
(ja)
|
2015-08-26 |
2018-09-06 |
ギリアード サイエンシーズ， インコーポレイテッド |
重水素化トール様受容体調節因子
|
|
JP2018529714A
(ja)
|
2015-09-30 |
2018-10-11 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖの処置のための化合物および組合せ物
|
|
PL3390441T3
(pl)
|
2015-12-15 |
2022-01-10 |
Gilead Sciences, Inc. |
Przeciwciała neutralizujące ludzki wirus niedoboru odporności
|
|
KR102375929B1
(ko)
|
2016-03-31 |
2022-03-16 |
온크터널 테라퓨틱스, 인코포레이티드. |
인돌린 유사체 및 이의 용도
|
|
TW202138365A
(zh)
|
2016-08-19 |
2021-10-16 |
美商基利科學股份有限公司 |
治療性化合物
|
|
WO2018042332A1
(en)
|
2016-08-31 |
2018-03-08 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combinations and uses and treatments thereof
|
|
WO2018042331A1
(en)
|
2016-08-31 |
2018-03-08 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combinations and uses and treatments thereof
|
|
MA46093A
(fr)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Composés modulateurs du recepteur de type toll
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
WO2018051250A1
(en)
|
2016-09-14 |
2018-03-22 |
Viiv Healthcare Company |
Combination comprising tenofovir alafenamide, bictegravir and 3tc
|
|
US10800772B2
(en)
|
2016-09-28 |
2020-10-13 |
Gilead Sciences, Inc. |
Therapeutic compounds
|
|
US10407438B2
(en)
|
2016-10-27 |
2019-09-10 |
Gilead Sciences, Inc. |
Crystalline forms of darunavir
|
|
CN106632019B
(zh)
*
|
2016-12-28 |
2019-05-28 |
太原理工大学 |
一种多取代吡啶的制备方法
|
|
AR110768A1
(es)
|
2017-01-31 |
2019-05-02 |
Gilead Sciences Inc |
Formas cristalinas de tenofovir alafenamida
|
|
AR110922A1
(es)
|
2017-02-06 |
2019-05-15 |
Gilead Sciences Inc |
Compuestos inhibidores del vih
|
|
TWI728250B
(zh)
|
2017-06-21 |
2021-05-21 |
美商基利科學股份有限公司 |
靶向hiv gp120及cd3之多特異性抗體
|
|
CN110958883A
(zh)
|
2017-06-30 |
2020-04-03 |
Viiv保健公司 |
组合及其用途和疗法
|
|
EP3661937B1
(en)
|
2017-08-01 |
2021-07-28 |
Gilead Sciences, Inc. |
Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
|
|
TWI687415B
(zh)
|
2017-08-17 |
2020-03-11 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
|
US20190151307A1
(en)
|
2017-10-24 |
2019-05-23 |
Gilead Sciences, Inc. |
Methods of treating patients co-infected with a virus and tuberculosis
|
|
KR102492187B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
|
|
JP7098748B2
(ja)
|
2017-12-20 |
2022-07-11 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
|
|
CN111836805B
(zh)
|
2018-02-15 |
2023-07-14 |
吉利德科学公司 |
吡啶衍生物及其用于治疗hiv感染的用途
|
|
TWI745652B
(zh)
|
2018-02-16 |
2021-11-11 |
美商基利科學股份有限公司 |
用於製備有療效化合物之方法及中間物
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
HUE071524T2
(hu)
|
2018-07-03 |
2025-09-28 |
Gilead Sciences Inc |
HIV GP120-at célzó antitestek és alkalmazási eljárások
|
|
US11944611B2
(en)
|
2018-07-16 |
2024-04-02 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of HIV
|
|
TWI829205B
(zh)
|
2018-07-30 |
2024-01-11 |
美商基利科學股份有限公司 |
抗hiv化合物
|
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
PE20211655A1
(es)
|
2018-10-31 |
2021-08-24 |
Gilead Sciences Inc |
Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
|
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
CN113543851B
(zh)
|
2019-03-07 |
2025-03-18 |
捷克共和国有机化学与生物化学研究所 |
2’3’-环二核苷酸及其前药
|
|
IL286328B1
(en)
|
2019-03-22 |
2026-04-01 |
Gilead Sciences Inc |
Tricyclic bridging compounds of carbamoylpyridone and their pharmaceutical use
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
WO2020214647A1
(en)
|
2019-04-17 |
2020-10-22 |
Gilead Sciences, Inc. |
Solid forms of an hiv protease inhibitor
|
|
CN111848443A
(zh)
*
|
2019-04-29 |
2020-10-30 |
南通泰禾化工股份有限公司 |
一种水杨腈的制备方法
|
|
TWI762925B
(zh)
|
2019-05-21 |
2022-05-01 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
RU2717101C1
(ru)
|
2019-06-03 |
2020-03-18 |
Андрей Александрович Иващенко |
Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
|
|
US20220305115A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
|
AU2020301161B2
(en)
|
2019-06-25 |
2023-10-26 |
Gilead Sciences, Inc. |
FLT3L-Fc fusion proteins and methods of use
|
|
AU2020315598B2
(en)
|
2019-07-16 |
2024-12-12 |
Gilead Sciences, Inc. |
HIV vaccines and methods of making and using
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
EP4643882A3
(en)
|
2019-11-26 |
2026-01-14 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of hiv
|
|
EP4445902A3
(en)
|
2019-12-24 |
2024-12-18 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
CR20220418A
(es)
|
2020-02-24 |
2022-10-10 |
Gilead Sciences Inc |
Compuestos tetracíclicos para el tratamiento de infecciones por vih
|
|
CA3169348A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
CN111548349A
(zh)
*
|
2020-05-13 |
2020-08-18 |
厦门云凡医药科技有限公司 |
一种ret激酶抑制剂中间体及其制备方法
|
|
WO2021236944A1
(en)
|
2020-05-21 |
2021-11-25 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
|
JP7520162B2
(ja)
|
2020-06-25 |
2024-07-22 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖの治療のためのカプシド阻害剤
|
|
ES3054072T3
(en)
|
2020-08-07 |
2026-01-29 |
Gilead Sciences Inc |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
CA3192145A1
(en)
|
2020-09-30 |
2022-04-07 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
JP7659628B2
(ja)
|
2020-11-11 |
2025-04-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
ｇｐ１２０ ＣＤ４結合部位指向性抗体による治療に感受性のＨＩＶ患者を特定する方法
|
|
JP7591155B2
(ja)
|
2021-01-19 |
2024-11-27 |
ギリアード サイエンシーズ， インコーポレイテッド |
置換ピリドトリアジン化合物及びその使用
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
PT4440702T
(pt)
|
2021-12-03 |
2025-08-13 |
Gilead Sciences Inc |
Compostos terapêuticos para a infecção pelo vírus do hiv
|
|
WO2023102523A1
(en)
|
2021-12-03 |
2023-06-08 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
|
JP7765637B2
(ja)
|
2021-12-03 |
2025-11-06 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖウイルス感染症のための治療化合物
|
|
TWI856796B
(zh)
|
2022-04-06 |
2024-09-21 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
EP4547659A1
(en)
|
2022-07-01 |
2025-05-07 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
|
KR20250036855A
(ko)
|
2022-07-12 |
2025-03-14 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 면역원성 폴리펩타이드 및 백신, 및 이들의 용도
|
|
WO2024044477A1
(en)
|
2022-08-26 |
2024-02-29 |
Gilead Sciences, Inc. |
Dosing and scheduling regimen for broadly neutralizing antibodies
|
|
EP4598934A1
(en)
|
2022-10-04 |
2025-08-13 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
|
AR132464A1
(es)
|
2023-04-19 |
2025-07-02 |
Gilead Sciences Inc |
Régimen de dosificación de inhibidor de la cápside
|
|
AU2024281548A1
(en)
|
2023-05-31 |
2025-11-13 |
Gilead Sciences, Inc. |
Solid forms of compounds useful in the treatment of hiv
|
|
EP4719608A1
(en)
|
2023-05-31 |
2026-04-08 |
Gilead Sciences, Inc. |
Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
|
|
AU2024283382A1
(en)
|
2023-05-31 |
2025-11-13 |
Gilead Sciences, Inc. |
Anti-hiv compounds
|
|
KR20260046169A
(ko)
|
2023-07-28 |
2026-04-06 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼
|
|
WO2025042394A1
(en)
|
2023-08-23 |
2025-02-27 |
Gilead Sciences, Inc. |
Dosing regimen of hiv capsid inhibitor
|
|
WO2025076542A1
(en)
|
2023-10-05 |
2025-04-10 |
Jones R Brad |
Atovaquone as an ros inducer for use in the elimination of hiv-infected t-cells
|
|
TW202515549A
(zh)
|
2023-10-11 |
2025-04-16 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
CN122055369A
(zh)
|
2023-10-11 |
2026-05-15 |
吉利德科学公司 |
桥连三环氨基甲酰基吡啶酮化合物及其用途
|
|
AU2024360779A1
(en)
|
2023-10-11 |
2026-04-16 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
US20250230163A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
US20250333424A1
(en)
|
2024-03-01 |
2025-10-30 |
Gilead Sciences, Inc. |
Antiviral compounds
|
|
US20250289822A1
(en)
|
2024-03-01 |
2025-09-18 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
US20250296932A1
(en)
|
2024-03-01 |
2025-09-25 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
TW202602461A
(zh)
|
2024-04-03 |
2026-01-16 |
美商基利科學股份有限公司 |
抗ｈｉｖ化合物
|
|
US20260007683A1
(en)
|
2024-06-14 |
2026-01-08 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
WO2026076265A1
(en)
|
2024-10-03 |
2026-04-09 |
Gilead Sciences, Inc. |
Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors
|